Page last updated: 2024-12-05

dibenzacridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dibenzacridine is a polycyclic aromatic hydrocarbon with a distinctive molecular structure characterized by two fused acridine units. Its synthesis typically involves multi-step reactions starting with anthracene derivatives and subsequent ring closures. Research on dibenzacridine has primarily focused on its potential applications in various fields, including:
1. **Materials science:** Dibenzacridine derivatives have shown promising fluorescence properties and have been investigated as potential organic semiconductors.
2. **Drug discovery:** Some dibenzacridine derivatives exhibit biological activity, specifically as anti-cancer agents.
3. **Photochemistry:** Dibenzacridine's photophysical properties make it a subject of interest in photochemistry research.
4. **Organic electronics:** Dibenzacridine derivatives have been explored for their potential applications in organic light-emitting diodes (OLEDs).
5. **Theoretical chemistry:** Dibenzacridine's complex structure provides a challenging system for theoretical studies on electronic structure and molecular properties.
6. **Environmental chemistry:** Dibenzacridine and its derivatives have been found in various environmental samples, prompting research into their potential toxicity and environmental fate.
The study of dibenzacridine continues to be driven by its unique structural features, diverse potential applications, and potential environmental impact.'

dibenzacridine: RN given refers to dibenz(a,j)acridine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9165
SCHEMBL ID730399
MeSH IDM0078088

Synonyms (25)

Synonym
dibenzo[a,c]acridine
dibenz[a,c]acridine
215-62-3
nsc-48754
nsc48754
dibenzacridine
dibenz(a,c)acridine
ccris 1891
nsc 48754
phenanthro[9,10-b]quinoline
65777-07-3
FT-0631875
AKOS015905544
SCHEMBL730399
dibenzo(a,c)acridine
GUZBPGZOTDAWBO-UHFFFAOYSA-N
dibenzo[a,c]acridine #
dibenz[a,c]acridine, bcr(r) certified reference material
J-014146
1,2,3,4-dibenzacridin
DTXSID40878543
15-azapentacyclo[12.8.0.0?,?.0?,??.0??,??]docosa-1,3,5,7,9,11,13,15,17,19,21-undecaene
dibenz (a,c) acridine (purity)
1,2:3,4-dibenzacridine
KHE7JV8NGB

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response relationships were obtained for DBa,hAC as well as for BaP."( Experimental studies on the carcinogenicity of five nitrogen containing polycyclic aromatic compounds directly injected into rat lungs.
Brune, H; Deutsch-Wenzel, RP; Grimmer, G, 1983
)
0.27
" Via intratracheal instillation, male CD rats (6/group) were dosed 3 times with BA, DBA, DBP or DBAC in a 24-h interval."( Induction of in vivo DNA adducts by 4 industrial by-products in the rat-lung-cell system.
Cutler, D; Ong, T; Stewart, JD; Whong, WZ, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (41.67)18.7374
1990's15 (41.67)18.2507
2000's4 (11.11)29.6817
2010's2 (5.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.22 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (94.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]